Lmcg Investments LLC Takes $5.60 Million Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Lmcg Investments LLC acquired a new position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 45,463 shares of the specialty pharmaceutical company's stock, valued at approximately $5,599,000. Lmcg Investments LLC owned approximately 0.08% of Jazz Pharmaceuticals at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in JAZZ. Itau Unibanco Holding S.A. acquired a new position in Jazz Pharmaceuticals in the second quarter worth about $29,000. EverSource Wealth Advisors LLC lifted its holdings in Jazz Pharmaceuticals by 55.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company's stock worth $30,000 after buying an additional 97 shares during the last quarter. UMB Bank n.a. grew its position in shares of Jazz Pharmaceuticals by 70.9% in the 4th quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company's stock worth $38,000 after acquiring an additional 129 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Jazz Pharmaceuticals by 41.3% in the 3rd quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company's stock valued at $46,000 after acquiring an additional 121 shares during the last quarter. Finally, Venturi Wealth Management LLC raised its position in shares of Jazz Pharmaceuticals by 577.0% during the 3rd quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company's stock valued at $92,000 after acquiring an additional 704 shares in the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total transaction of $185,145.00. Following the completion of the sale, the chief executive officer now owns 425,525 shares in the company, valued at approximately $52,522,550.75. This represents a 0.35 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Neena M. Patil sold 3,700 shares of Jazz Pharmaceuticals stock in a transaction on Friday, November 8th. The stock was sold at an average price of $123.41, for a total value of $456,617.00. Following the completion of the transaction, the executive vice president now owns 33,048 shares in the company, valued at $4,078,453.68. The trade was a 10.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 8,253 shares of company stock valued at $1,001,434 over the last three months. Company insiders own 4.20% of the company's stock.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. Piper Sandler reiterated an "overweight" rating and set a $163.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. TD Cowen cut their target price on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a "buy" rating on the stock in a report on Thursday, November 7th. Robert W. Baird upped their target price on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an "outperform" rating in a report on Monday, November 18th. Royal Bank of Canada reissued an "outperform" rating and issued a $179.00 price target on shares of Jazz Pharmaceuticals in a report on Tuesday, December 10th. Finally, HC Wainwright restated a "buy" rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Two investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $177.00.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ stock traded up $0.25 during mid-day trading on Tuesday, hitting $121.43. 538,623 shares of the stock traded hands, compared to its average volume of 486,035. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $134.17. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The company's 50-day simple moving average is $122.66 and its 200-day simple moving average is $114.87. The firm has a market cap of $7.34 billion, a price-to-earnings ratio of 17.10, a price-to-earnings-growth ratio of 0.88 and a beta of 0.56.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.